We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+45.38%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.7B
AUM Growth
+$6.43B
Cap. Flow
-$298M
Cap. Flow %
-1.32%
Top 10 Hldgs %
85.22%
Holding
124
New
14
Increased
20
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$116M
2
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$86.7M
3
ADCT icon
ADC Therapeutics
ADCT
+$64M
4
NVTA
Invitae Corporation
NVTA
+$48M
5
SYRE icon
Spyre Therapeutics
SYRE
+$20.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$416M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$101M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$36.8M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.68%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$8.03B 35.43%
47,269,424
-2,790,816
-6% -$416M
INCY icon
2
Incyte
INCY
$25.9B
$3.33B 14.67%
31,999,081
+20,296
+0.1% +$1.96M
ONC
3
BeOne Medicines Ltd
ONC
$42.4B
$2.22B 9.79%
11,777,285
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$5.08B
$2.03B 8.96%
41,904,586
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$983M 4.34%
8,760,794
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.9B
$936M 4.13%
7,589,294
– –
KOD icon
7
Kodiak Sciences
KOD
$2.41B
$626M 2.76%
11,574,538
– –
ASND icon
8
Ascendis Pharma A/S
ASND
$16.6B
$501M 2.21%
3,390,270
– –
NVTA
9
DELISTED
Invitae Corporation
NVTA
$359M 1.58%
11,850,962
+2,750,347
+30% +$48M
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$306M 1.35%
3,164,234
+1,390,000
+78% +$116M
AMRN
11
Amarin Corp
AMRN
$298M
$239M 1.05%
1,724,834
– –
ARGX icon
12
argenx
ARGX
$65B
$230M 1.01%
1,019,557
– –
IGMS
13
DELISTED
IGM Biosciences
IGMS
$230M 1.01%
3,144,223
+223
+0% +$13.5K
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$11.9B
$170M 0.75%
1,499,212
– –
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$161M 0.71%
1,409,784
– –
EXAS
16
DELISTED
Exact Sciences
EXAS
$161M 0.71%
1,846,139
– –
NBIX icon
17
Neurocrine Biosciences
NBIX
$15.5B
$111M 0.49%
906,986
-333,257
-27% -$36.8M
PRNB
18
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$94.5M 0.42%
1,580,873
-374,540
-19% -$23.1M
FMTX
19
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$93M 0.41%
+2,000,000
New +$86.7M
CERS icon
20
Cerus
CERS
$566M
$90.5M 0.4%
13,713,195
– –
HRTX icon
21
Heron Therapeutics
HRTX
$60.4M
$88.5M 0.39%
6,018,104
– –
INSM icon
22
Insmed
INSM
$27.5B
$83.3M 0.37%
3,025,384
– –
AXSM icon
23
Axsome Therapeutics
AXSM
$10.9B
$83.1M 0.37%
1,009,757
+120,000
+13% +$9.24M
ADCT icon
24
ADC Therapeutics
ADCT
$127M
$79M 0.35%
+1,687,500
New +$64M
BCEL
25
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$75.2M 0.33%
3,532,760
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2020 Portfolio in Review

As of Q2 2020, Julian Baker held 124 positions worth $22.7B, up 40% from $16.2B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q2 2020 filing shows 14 new, 20 increased, 17 reduced and 10 closed positions. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M. The largest sale was Seagen Inc. Common Stock, an estimated $416M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M.
  • Julian Baker added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $116M increase.
  • Julian Baker's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $416M.
  • Julian Baker fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $101M.
  • Julian Baker's ten largest holdings make up 85% of its $22.7B portfolio in Q2 2020.
  • Julian Baker opened 14 new positions and closed 10 in Q2 2020.
  • Julian Baker's portfolio value rose 40% quarter-over-quarter to $22.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.